Amended Current Report Filing (8-k/a)
March 07 2022 - 4:02PM
Edgar (US Regulatory)
0001622879
true
The Company is filing this Amendment No. 2 to Current Report on Form 8-K/A (this "Amendment") to file the consent from the auditor, Crowe LLP, which was inadvertently omitted from the Original Form 8-K Amendment.
0001622879
2021-03-02
2021-03-02
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K/A
(Amendment
No. 2)
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
Date of Report (Date of earliest event
reported): March 2, 2021
Medicine Man
Technologies, Inc.
(Exact Name of Registrant as
Specified in Its Charter)
Nevada |
|
000-55450 |
|
46-5289499 |
(State or Other Jurisdiction of Incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
4880 Havana Street, Suite 201
Denver, Colorado |
80239 |
(Address of Principal Executive Offices) |
(Zip Code) |
|
|
(303) 371-0387 |
(Registrant’s Telephone Number, Including Area Code) |
|
|
Not Applicable |
(Former Name or Former Address, if Changed Since Last Report) |
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b)
of the Act:
Title of Each Class |
|
Trading Symbol(s) |
|
Name of Each Exchange On Which Registered |
Not applicable |
|
Not applicable |
|
Not applicable |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.
Explanatory Note
On March 8, 2021, Medicine Man Technologies, Inc.
(the “Company”) filed a Current Report on Form 8-K to report, among other things, the completion of its acquisition of the
assets of SB Arapahoe LLC and KEW LLC (the “Original Form 8-K”). On May 18, 2021, the Company filed an Amendment to Current
Report on Form 8-K/A to the Original Form 8-K to provide the financial statements and pro forma financial information required by Items
9.01(a) and 9.01(b), respectively, of Form 8-K (the “Original Form 8-K Amendment,” and together with the Original Form 8-K,
the “Original Filings”).
The Company is filing this Amendment No. 2 to Current
Report on Form 8-K/A (this “Amendment”) to file the consent from the auditor, Crowe LLP, which was inadvertently omitted from
the Original Form 8-K Amendment. The Company is restating Item 9.01 in its entirety and adding to the exhibit index references to all
relevant exhibits. This Amendment does not modify, amend, or update in any way any of the financial or other information contained in
the Original Filings, nor does it reflect events that may have occurred subsequent to the filing dates of the Original Filings.
Item 9.01 Financial Statements and Exhibits.
(a) Financial Statements of Business Acquired
1. The unaudited financial statements
of SB Arapahoe LLC and KEW LLC and the notes thereto, for the nine months ended September 30, 2020 and 2019, are included as Exhibit 99.1
hereto and are incorporated herein by reference.
2. The audited financial statements
of SB Arapahoe LLC and KEW LLC and the notes thereto, for the year ended December 31, 2019, are included as Exhibit 99.1 hereto and are
incorporated herein by reference.
(b) Pro Forma Financial Information
The following unaudited pro forma condensed combined
financial information of the Company, giving effect to the SB Arapahoe LLC and KEW LLC purchase agreements, is included in Exhibit 99.2
hereto and is incorporated herein by reference:
1. Unaudited Pro Forma Condensed
Combined Balance Sheet as of September 30, 2020;
2. Unaudited Pro Forma Condensed
Combined Statement of Operations for the nine months ended September 30, 2020; and
3. Unaudited Pro Forma Condensed
Combined Statement of Operations for the year ended December 31, 2019.
(d) Exhibits
2.1 |
|
Asset Purchase Agreement, dated June 5, 2020, by and among Medicine Man Technologies, Inc., SBUD LLC, SB Arapahoe LLC and the Members named therein (Incorporated by reference to Exhibit 2.6 to Medicine Man Technologies, Inc.’s Current Report on Form 8-K filed on June 8, 2020 (Commission File No. 000-55450)) |
|
|
|
2.2 |
|
Asset Purchase Agreement, dated June 5, 2020, by and among Medicine Man Technologies, Inc., SBUD LLC, Kew LLC and the Members named therein (Incorporated by reference to Exhibit 2.4 to Medicine Man Technologies, Inc.’s Current Report on Form 8-K filed on June 8, 2020 (Commission File No. 000-55450)) |
|
|
|
2.3 |
|
Asset Purchase Agreement, dated June 5, 2020, by and among Medicine Man Technologies, Inc., SBUD LLC, Starbuds Aurora LLC and the Members named therein (Incorporated by reference to Exhibit 2.5 to Medicine Man Technologies, Inc.’s Current Report on Form 8-K filed on June 8, 2020 (Commission File No. 000-55450)) |
|
|
|
2.4 |
|
Asset Purchase Agreement, dated June 5, 2020, by and among Medicine Man Technologies, Inc., SBUD LLC, Citi-Med LLC and the Members named therein (Incorporated by reference to Exhibit 2.2 to Medicine Man Technologies, Inc.’s Current Report on Form 8-K filed on June 8, 2020 (Commission File No. 000-55450)) |
|
|
|
2.5 |
|
Asset Purchase Agreement, dated June 5, 2020, by and among Medicine Man Technologies, Inc., SBUD LLC, Starbuds Louisville LLC and the Members named therein (Incorporated by reference to Exhibit 2.9 to Medicine Man Technologies, Inc.’s Current Report on Form 8-K filed on June 8, 2020 (Commission File No. 000-55450)) |
|
|
|
2.6 |
|
Omnibus Amendment No. 1 to Asset Purchase Agreements, dated September 20, 2020, by and among Medicine Man Technologies, Inc., SBUD LLC, and each signatory thereto designated as a Seller (Incorporated by reference to Exhibit 2.1 to Medicine Man Technologies, Inc.’s Current Report on Form 8-K filed on September 21, 2020 (Commission File No. 000-55450)) |
|
|
|
2.7* |
|
Omnibus Amendment No. 2 to Asset Purchase Agreements, dated December 17, 2020, by and among Medicine Man Technologies, Inc., SBUD LLC, and each signatory thereto designated as a Seller (Incorporated by reference to Exhibit 2.1 to Medicine Man Technologies, Inc.’s Current Report on Form 8-K filed on December 23, 2020 (Commission File No. 000-55450)) |
|
|
|
23.1 |
|
Consent of Crowe LLP |
|
|
|
99.1 |
|
SB Arapahoe LLC and KEW LLC Unaudited Financial Statements for the nine months ended September 30, 2020 and 2019 and the Audited Financial Statements for the year ended December 31, 2019 (Incorporated by reference to Exhibit 99.1 to Medicine Man Technologies, Inc.’s Current Report on Form 8-K/A filed on May 18, 2021 (Commission File No. 000-55450) |
|
|
|
99.2 |
|
Unaudited Pro Forma Condensed Combined Financial Information (Incorporated by reference to Exhibit 99.2 to Medicine Man Technologies, Inc.’s Current Report on Form 8-K/A filed on May 18, 2021 (Commission File No. 000-55450) |
|
|
|
99.3 |
|
Press Release, dated March 3, 2021 (Incorporated by reference to Exhibit 99.1 to Medicine Man Technologies, Inc.’s Current Report on Form 8-K filed on March 8, 2021 (Commission File No. 000-55450)) |
|
|
|
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
* Certain schedules have been omitted pursuant to Item 601(b)(2)
of Regulation S-K under the Securities Exchange Act of 1934, as amended. The Company hereby undertakes to supplementally furnish copies
of any omitted schedules to the Securities and Exchange Commission upon request.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
MEDICINE MAN TECHNOLOGIES, INC. |
|
|
|
|
|
|
|
By: |
/s/ Daniel R. Pabon |
|
|
Daniel R. Pabon |
|
|
General Counsel |
Date: March 7, 2022
Medicine Man Technologies (QX) (USOTC:SHWZ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medicine Man Technologies (QX) (USOTC:SHWZ)
Historical Stock Chart
From Apr 2023 to Apr 2024